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Abstract
Background: It has been suggested that the B-cell specific moloney leukemia virus insertion site 1 (Bmi-1) gene
plays an oncogenic role in several types of human cancer, but the status of Bmi-1 amplification and expression in
ovarian cancer and its clinical/prognostic significance are unclear.
Methods: The methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine
protein expression and amplification of Bmi-1 in 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian
tumors and 179 ovarian carcinomas.
Results: Intensive expression of Bmi-1 was detected in none of the normal ovaries, 3% cystadenomas, 10%
borderline tumors, and 37% ovarian carcinomas, respectively. Amplification of Bmi-1 was detected in 8% of ovarian
carcinomas. In ovarian carcinomas, significant positive associations were found between intensive expression of
Bmi-1 and the tumors ascending histological grade, later pT/pN/pM and FIGO stages (P < 0.05). In univariate
survival analysis of the ovarian carcinoma cohorts, a significant association of intensive expression of Bmi-1 with
shortened patient survival (mean 49.3 months versus 100.3 months, p < 0.001) was demonstrated. Importantly, Bmi-
1 expression provided significant independent prognostic parameters in multivariate analysis (p = 0.005).
Conclusions: These findings provide evidence that intensive expression of Bmi-1 might be important in the
acquisition of an invasive and/or aggressive phenotype of ovarian carcinoma, and serve as a independent
biomarker for shortened survival time of patients.
Background
Ovarian cancer is a major lethal gynecological malig-
nancy worldwide [1]. Its peak incidence is at the age 45
or above. Because of its insidious onset, approximately
70% of ovarian cancer patients were diagnosed at
advanced stage(FIGO III/IV stage) with a very poor
prognosis, whose 5-year survival rate is of <30% [2].
Ovarian carcinoma is the most common histopathologi-
cal type of ovarian cancer. The development and pro-
gression of ovarian carcinoma are presumed to be a
multi-step process involving multiple genetic changes
[3]. Thus, a substantial amount of research on ovarian
carcinoma has focused on the discovery of specific
molecular markers that are present in ovarian carcinoma
cells which could serve as reliable prognostic factors.
The B-cell specific moloney leukemia virus insertion
site 1 (Bmi-1) gene belongs to mammalian Polycomb-
group (PcG) family forming multimeric gene-repressing
complexes involved in axial patterning, hematopoiesis,
regulation of proliferation, and senescence. Bmi-1 was
first identified as a proto-oncogene that cooperated with
c-Myc in generating pre-B-cell lymphomas in a murine
model [4-8]. It has been discovered that Bmi-1 partici-
pates in cell cycle regulation by acting as a stable tran-
scriptional repressor of the Ink4a locus, which encodes
the tumor suppressor proteins p16Ink4a and p19Arf
(mouse homologue of human p14ARF). Inactivation of
the p16Ink4a-pRb pathway and p14ARF-MDM2-p53
pathway by Bmi-1 deregulation has been clearly
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implicated in lymphomagenesis [9,10] and oncogenesis
in nonsmall-cell lung cancer of human [11]. This sug-
gested that the Bmi-1 gene plays an important role in
cell proliferation and tumor progression. It has been
confirmed that Bmi-1 gene is widely expressed in
diverse human tumors, including non-small cell lung
cancer, hepatocellular carcinoma, B-cell non-Hodgkin’s
lymphoma, breast cancer, ovarian cancer, colorectal can-
cer, skin cancer and neuroblastoma [10-20], and has
been shown to be a useful prognostic marker in myelo-
dysplastic syndrome and many cancers, including naso-
pharyngeal carcinoma, bladder cancer and gastric cancer
[17-20].
To date, however, the status of Bmi-1 expression and
its clinical/prognostic relevance in ovarian cancer have
not been fully elucidated. In this study, the protein
expression and amplification status of Bmi-1 in a series
of human epithelial ovarian tissue, normal and patholo-
gical, non-neoplastic and neoplastic, were examined.
The clinico-pathological and prognostic significance of
expression of Bmi-1 in our ovarian carcinoma cohorts
was also assessed.
Methods
Patients and tissue specimens
In this study, a total of 249 epithelial ovarian tumors
(benign, borderline and carcinomatous) were obtained
from archives of paraffin-embedded tissues between
1996 and 2008 at the Department of Pathology, Cancer
Center and the First Affiliated Hospital, Sun Yat-Sen
University, Guangzhou, China. The cancer cases selected
were based on availability of resection tissue and follow-
up data. Patients whose cause of death remained
unknown were excluded from our study. The ovarian
tumor cases encompassed 179 histologically confirmed
invasive carcinomas, 40 borderline tumors and 30 cysta-
denomas. Data of survival time and clinico-pathological
parameters were collected. Ages of the 179 patients with
ovarian carcinoma ranged from 18 to 86 years (mean
age, 50.7 years) and their clinico-pathological character-
istics are summarized in Table 1. None of the cancer
patients in this study had received preoperative radiation
or chemotherapy. In addition, 30 specimens of normal
ovaries from exairesis for non-ovary diseases in the
Department of Gynaecology and Obstetrics of the First
Affiliated Hospital, Sun Yat-Sen University from 2005 to
2008 were used as control. For the use of these clinical
materials for research purposes, prior patient’s consent
and approval from the Institute Research Medical Ethics
Committee of Sun Yat-Sen University was obtained.
Construction of tissue microarrays (TMA)
The TMA was constructed according to a method
described previously [21]. Briefly, the individual donor
tissue block and the corresponding histological H&E
stained slides were overlaid for tissue TMA sampling.
The tissues (179 ovarian carcinoma, 40 borderline
tumor, and 30 cystadenoma tissues) were sampled using
a tissue arraying instrument (Beecher Instruments, Silver
Spring, MD); a 0.6-mm-diameter cylinder of tissue was
removed. Subsequently, the tissue cylinder was re-
embedded into a predetermined position in a recipient
paraffin block. In our constructed ovarian tumor tissue-
TMA, 3 cores of sample were selected from each tumor
tissue. Multiple sections (5 μm thick) were cut from the
TMA block and mounted on microscope slides.
Immunohistochemistry (IHC)
IHC studies were performed using a standard streptavi-
din-biotin-peroxidase complex method [22]. For antigen
retrieval, tissue slides were microwave-treated and
boiled in a 10 mM citrate buffer (pH 6.0) for 10 min.
The slides were incubated with rabbit monoclonal anti-
body against human Bmi-1 (Shangying Biotechnology
Inc. Wuhan, China, 1:2000 dilution), mouse monoclonal
antibodies against human p16Ink4a (1:200 dilution) or
p14ARF (1:300 dilution, Labvision Co., Neomarkers,
USA) overnight at 4°C in a moist chamber. A negative
control was obtained by replacing the primary antibody
with normal rabbit or mouse IgG. Known immunostain-
ing positive slides were used as positive controls.
Expression levels of Bmi-1 protein were visualized by
observing the stained tissues under a light microscope.
Positive expression of Bmi-1 was defined as the presence
of brown or yellowish brown granules in the nuclei,
though occasionally yellowish brown granules could also
be seen in the cytoplasm. For evaluation of the Bmi-1
IHC staining in different ovarian tissues, a semi-quanti-
tative scoring criterion for IHC of Bmi-1 described pre-
viously [16] was used, in which both staining intensity
and positive areas were recorded. A staining index
(values 1 to 16), obtained as the intensity of Bmi-1 posi-
tive staining (negative = 1, weak = 2, moderate = 3, or
strong = 4 scores) and the proportion of immunoposi-
tive cells of interest (≤ 10% = 1, >10% to ≤ 50% = 2,
>50% to ≤ 75% = 3, >75% = 4 scores) were calculated.
The two different scores of corresponding sample were
then multiplied. Points equal or less than 4 was marked
as (-); 4 points to 8 points was marked as (+); 8 points
to 12 points, (++); and 12 points to 16 points, (+++).
For statistical analysis, (-) and (+) were counted as low
expression of Bmi-1 (Fig. 1A, B and 1C), while (++) and
(+++) were counted as intensive expression of Bmi-1
(Fig. 1D and 1E). The evaluation of p16Ink4a and
p14ARF IHC staining was scored on a semi-quantitative
scale [14], as follows: negative expression (<10% of the
cells were positive), down-regulated expression (small
cell clusters, but 10-50% of the cells were positive) and
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diffuse expression (>50% of the cells were positive).
Results were observed and assessed by two independent
pathologic doctors, without knowing the identity of the
samples.
Fluorescence in situ hybridization (FISH)
Two-color FISH was performed using a Spectrum
Orange-labeled BAC clone (RP11-573G6) at 10p12 con-
taining the Bmi-1 gene and a Spectrum Green-labeled
reference centromeric probe on chromosome 10 (Vysis,
Downers Grove, IL). The FISH reaction was performed
as described previously [23] with slight modification.
Briefly, deparaffinized ovarian carcinoma tissue sections
were treated with proteinase K (400 μg/ml) at 37°C for
30 min, followed by denaturing in 70% formamide, 2×
SSC at 75°C for 6 min. Fifty nanograms of each probe
were mixed in a 20 μl hybridization mixture (containing
55% formamide, 2× SSC, and 2 ∝g human Cot1 DNA),
denatured at 75°C for 6 min and then hybridized to the
denatured tissue sections at 37°C for 24 hours. The
slides were counterstained with 1 μg/ml DAPI in an
anti-fade solution and were examined with a Zeiss Axio-
phot microscope equipped with a triple-band pass filter.
A minimum of 300 tumor cells was evaluated per speci-
men. Amplification of Bmi-1 was defined as presence of
either 6 (or more) Bmi-1 gene signals or at least 3 times
as many gene signals than centromere signals of chro-
mosome 10 in tumor cells (Fig. 1F).
Statistical analyses
Statistical analysis was carried out with the SPSS statisti-
cal software package (SPSS Standard version 13.0, SPSS
Inc.). The association of Bmi-1 protein expression with
ovarian carcinoma patient’s clinico-pathological features
was assessed by the Chi-square test. Multivariate survival
analysis was performed on all parameters that were
Table 1 Association of Bmi-1 expression with patient’s clinico-pathological features in ovarian carcinomas
Bmi-1 protein
All cases Low expression Intensive expression P valuea
Age at surgery (years) 0.452
≤ 50.7b 92 60 (65%) 32 (35%)
> 50.7 87 52 (60%) 35 (40%)
Histological type 0.038
Serous (grade 1) 11 9 (82%) 2 (18%)
Serous (grade2/3) 107 68 (64%) 39 (36%)
Mucinous 23 15 (65%) 8 (35%)
Endometrioid 8 7 (88%) 1 (12%)
Clear cell 7 5 (71%) 2 (29%)
Undifferentiated 23 8 (35%) 15 (65%)
Histological grade (Silveberg) 0.011
G1 36 29 (81%) 7 (19%)
G2 101 63 (62%) 38 (38%)
G3 42 20 (48%) 22 (52%)
pT status 0.037
pT1 51 39 (76%) 12 (24%)
pT2 35 22 (63%) 13 (37%)
pT3 93 51 (55%) 42 (45%)
pN status 0.001
pN0 88 66 (75%) 22 (25%)
pN1 91 46 (51%) 45 (49%)
pM status 0.006
pMX 153 102 (67%) 51 (33%)
pM1 26 10 (38%) 16 (62%)
FIGO stage 0.002
I 33 27 (82%) 6 (18%)
II 21 17 (81%) 4 (19%)
III 99 58 (59%) 41 (41%)
IV 26 10 38%) 16 (62%)
aChi-square test
bMean age
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Figure 1 Immunohistochemical staining of Bmi-1 protein and Fluorescence in situ hybridization of Bmi-1 gene in human ovarian
tissues. (A) Negative expression of Bmi-1 was observed in a normal surface epithelium of ovary (200×). (B) An ovarian cystadenoma showed low
expression of Bmi-1, in which about 10% of tumor cells was detected moderate positive staining of Bmi-1 (200×). (C) Low expression of Bmi-1
was observed in an borderline ovarian tumors, in which 5% of tumor cells showed weak positive staining of Bmi-1 (200×). (D) Intensive
expression of Bmi-1 was detected in an ovarian carcinoma (case 33), in which more than 90% of carcinoma cells showed strong positive staining
of Bmi-1 (200×). (E) Another ovarian carcinoma (case 161) showed intensive expression of Bmi-1, in which all of tumor cells had strong positive
staining of Bmi-1 (200×). (F) Amplification of Bmi-1 gene was observed by FISH in the same ovarian carcinoma case (161), in which Bmi-1 gene
signals (red) was detected at least 3 times more than centromere signals of chromosome 10 (green) (1000×).
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found to be significant on univariate analysis using the
Cox regression model. For univariate survival analysis, we
analyzed all ovarian carcinoma patients by Kaplan-Meier
analysis. Log rank test was used to compare different sur-
vival curves. P < 0.05 was considered significant.
Results
Bmi-1 expression in ovarian tissues
Bmi-1 expression could be evaluated informatively in
TMA tissues of 163/179 of ovarian carcinomas, 37/40 of
borderline tumors and 26/30 of cystadenomas. The non-
informative TMA samples included unrepresentative
samples, samples with too few tumor cells (<300 cells
per case) and lost samples. IHC staining of such non-
informative samples were replaced and performed by
using whole tissue slides. In our study, we defined that
(-) and (+) were counted as low expression of Bmi-1,
while (++) and (+++) were counted as intensive expres-
sion of Bmi-1. According to this definition, the intensive
expression of Bmi-1 was detected in 67/179 (37%) ovar-
ian carcinomas. The increasing frequencies of Bmi-1
intensive expression in normal ovarian epithelium (0), to
benign cystadenomas (3%), to borderline tumors (10%),
and to invasive carcinomas were significant (37%, P <
0.05, Table 2).
Association of Bmi-1 expression with ovarian carcinoma
patient clinico-pathologic features
The association between Bmi-1 expression in ovarian
carcinomas and several known clinico-pathological fea-
tures was further studied. Bmi-1 expression was posi-
tively correlated with tumors histological type, grade,
pT/pN/pM status, and FIGO stage (P < 0.05, Table 2).
No significant correlation was obtained between Bmi-1
expression and patient age (≤ 50.7 years vs > 50.7 years)
(P > 0.05, Table 1).
Relationship between clinicopathologic variables, Bmi-1
expression and ovarian carcinoma patient survival:
Univariate survival analysis
In univariate survival analyses, cumulative survival
curves were calculated according to the Kaplan-Meier
method. Differences in survival times were assessed with
the log-rank test. First, to confirm the representativeness
of the ovarian carcinomas in our study, we analyzed
established prognostic predictors of patient survival.
Kaplan-Meier analysis demonstrated a significant impact
of well-known clinical pathological prognostic para-
meters, such as tumor histological grade (p = 0.012),
pT/pN/pM status (p < 0.01) and FIGO stage (p < 0.001)
on patient survival (Table 3). The mean survival time
for patients with tumors having intensive expression of
Bmi-1 was 49.3 months compared to 100.3 months for
pateints with tumors having low expression of Bmi-1
Table 2 The expression of Bmi-1 in normal ovaries and in
benign and malignant epithelial ovarian tumorsa
Bmi-1 protein
All cases Low expression Intensive expression
Normal ovaries 30 30 (100%) 0 (0)
Cystadenomas 30 29 (97%) 1 (3%)
Borderline tumors 40 36 (90%) 4 (10%)
Invasive carcinomas 179 112 (63%) 67 (37%)
aValues are n (%). A significant increasing frequency of intensive expression of
Bmi-1 was observed in cystadenomas, in borderline tumors and in invasive
carcinomas (P < 0.01, Chi-Square Test for Trend)
Table 3 Clinical pathological parameters and expression
of Bmi-1 for prognosis of 179 patients with ovarian
carcinoma by univariate survival analysis (log-rank test)
Variable All
cases
Mean
survival
(months)
Median
survival
(months)
P
value
Age at surgery (years) 0.388
≤ 50.7a 92 83.4 136.0
> 50.7 87 81.7 55.0
Histological type 0.491
Serous(grade 1) 11 110.4 136.0
Serous(grade2/3) 107 63.4 52.0
Mucinous 23 75.8 NRb
Endometrioid 8 116.7 NR
Clear cell 7 102.8 NR
Undifferentiated 23 32.7 NR
Histological grade
(Silveberg)
0.012
G1 36 104.9 136.0
G2 101 85.9 64.0
G3 42 48.0 29.0
pT status 0.003
pT1 51 109.5 NR
pT2 35 82.2 NR
pT3 93 66.5 35.0
pN status <0.001
pN0 88 100.9 136.0
pN1 91 52.8 28.0
pM status <0.001
pMX 153 94.8 136.0
pM1 26 21.5 9.0
FIGO stage <0.001
I 33 134.2 NR
II 21 115.0 NR
III 99 71.5 37.0
IV 26 21.5 9.0
Bmi-1 expression <0.001
Low 112 100.3 136.0
Intensive 67 49.3 22.0
aMean age
bNot reached
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(P < 0.001, Fig. 2, Table 3). In stratified survival analysis,
Bmi-1 expression could stratify the outcome of patients
in hige-grade (grade 2/3) serous carcinoma (P = 0.045),
mucinous carcinoma (P = 0.001) and undifferentiated
carcinoma (P = 0.001) subgroups.
Independent prognostic factors of ovarian carcinoma:
Multivariate Cox regression analysis
Since variables observed to have prognostic influence by
univariate analysis may covariate, the expression of Bmi-
1 as well as other clinical pathological parameters that
were significant in univariate analysis (pN stage and
FIGO stage) was examined in multivariate analysis
(Table 4). The expression of Bmi-1 was found to be an
independent prognostic factor for poor overall survival
(relative risk: 1.998, CI: 1.228-3.251, P = 0.005). Of the
other parameters, pN stage (P = 0.010) and FIGO stage
(P = 0.004) were also demonstrated as independent
prognostic factor for overall survival.
Amplification of Bmi-1 in ovarian tumor TMA
In our FISH study, the FISH analysis was informative in
96/179 of ovarian carcinomas, 21/40 of borderline ovar-
ian tumors and 15/30 of ovarian cystadenomas. Samples
without FISH signal and samples with weak target signals
or those with a strong signal background were the main
reasons for most of the non-informative cases. FISH
results demonstrated that the amplification of Bmi-1 was
not detected in any of the ovarian cystadenoma and bor-
derline tumor tissues; but was detected in 8% (8/96) of
the informative ovarian carcinomas; in each of the 8
cases with Bmi-1 amplification, intensive expression of
Bmi-1 was observed (Fig. 1E and 1F). In the remaining
88 informative cancers without amplification of Bmi-1,
Figure 2 Kaplan-Meier survival analysis according to Bmi-1 expression in 179 patients with invasive ovarian carcinoma (log-rank test).
Probability of survival of patients: low expression of Bmi-1, n = 112; intensive expression of Bmi-1, n = 67 (p < 0.001).
Table 4 Multivariate analysis on overall survival (Cox
regression model)
Variable Relative risk 95% Confidence interval P value
Bmi-1a 1.998 1.228-3.251 0.005
Histological gradeb 0.940 0.614-1.439 0.777
pT statusc 1.189 0.788-1.793 0.409
pN statusd 2.016 1.184-3.432 0.010
pM statuse 0.975 0.280-3.393 0.975
FIGO stagef 3.686 1.521-8.931 0.004
aIntensive expressin vs Low expression
bG1 vs G2 vs G3
cpT1 vs pT2 vs pT3
dpN0 vs pN1
epMX vs pM1
fStage I vs Stage II vs Stage III vs StageIV
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60 (68%) cases showed low expression of Bmi-1, while 28
(32%) cases were observed intensive expression of Bmi-1.
Correlation between the expression of Bmi-1 and
p16Ink4a and p14ARF in ovarian carcinomas
Since it was suggested that modulation of Bmi-1 protein
might be involved in human colorectal carcinogenesis
by repressing p16Ink4a/p14ARF proteins {14}, we
further examined the expression of p16Ink4a/p14ARF
by IHC in our ovarian carcinoma cohorts. By utilizing
the criterion of a semi-quantitative scale as previously
described [14], we found that 36% (64/179) and 17%
(30/179) of ovarian carcinomas had negative/down-regu-
lated expression of p16Ink4a and p14ARF, respectively.
Further correlation analysis demonstrated that no signif-
icant correlation between Bmi-1 expression and expres-
sion of either p16Ink4a or p14ARF was evaluated in
these ovarian carcinoma cohorts (P > 0.05, Fishers exact
test).
Discussion
In recent years, the incidence of ovarian carcinoma has
been increasing in Asian countries such as China and
Singapore [24]. The available clinicopathologic prognos-
tic indicators are not accurate, although the treatment
of ovarian cancer has been improved greatly in recent
years, its 5-year survival rate is of <30% [2]. Thus, it is
important to identify a biological genetic molecular mar-
ker that is associated with pathophysiologic processes of
human ovarian cancer.
The gene, Bmi-1, was initially shown to regulate hae-
matopoiesis and differentiation of lymphocytes [25] and
to be involved in cerebral development [26]. To date,
the proto-oncogene Bmi-1 has been reported to be up-
regulated in a large number of neoplasias, namely in
lymphomas [27], cerebral tumours [26], breast cancer
[13] and other epithelial tumours [28,29] and to be an
oncogene associated with poor prognosis in various
tumours [12]. To investigate whether or not the abnor-
mal expression of Bmi-1 is involved in the pathogenesis
of ovarian carcinoma, in the present study, the protein
expression of Bmi-1 was examined firstly by IHC in nor-
mal ovaries, benign and borderline epithelial ovarian
tumors, and malignant epithelial cancers. The results
demonstrated that the expression of Bmi-1 in all of the
normal ovary specimens was absent or at low levels. In
our ovarian tumor specimens, a significant increasing
expression of Bmi-1 was observed from benign cystade-
noma to borderline tumor, and to carcinoma. In addi-
tion, we found that the frequency of intensive
expression of Bmi-1 in undifferentiated ovarian carcino-
mas was significantly larger than that in other types of
carcinoma. In serous carcinomas, intensive expression of
Bmi-1 was more likely to be observed in grade 2/3
tumors than that in grade 1 tumors. Furthermore, inten-
sive expression of Bmi-1 in our ovarian carcinoma
cohorts was strongly correlated with an ascending histo-
logical grade and clinical stage (pT/pN/pM and FIGO
stage) of the tumor. These findings suggest that up-
regulated expression of Bmi-1 in ovarian carcinoma may
represent an acquired malignant phenotypic feature of
tumor cells.
Datas from several clinical studies show that abnormal
expression of Bmi-1, in protein level as well as in gene
level, is favorably associated with poor prognostic mar-
kers and clinical outcome in diverse human cancers,
such as colorectal cancer, nasopharyngeal carcinoma,
bladder cancer and myelodysplastic syndrome
[14,17-19]. However, to our best knowledge, there is lit-
tle information about prognostic status and clinical out-
come of Bmi-1 expression in ovarian cancer. This is the
first study evaluating the expression of Bmi-1 by IHC, in
association with clinicopathological and prognostic sig-
nificance for a large number of ovarian cancer patients.
Consistent with previous reports of other types of
human cancer, in this study, we found that intensive
expression of Bmi-1 in ovarian carcinoma was a predic-
tor of short overall survival, independent of stage and
grade. These findings raise the question of a potentially
why important role of Bmi-1 as an underlying biological
mechanism in the development and/or growth of
human cancers.
It is known, the encoded protein of Bmi-1, as well as
other proteins from the PcG family, can block the tran-
scription of some genes such as p16Ink4a and p19Arf
involved in tumour suppression, resulting in oncogenic
effects [14]. In our previous investigation, however, we
found that Bmi-1 may promote immortalization of naso-
pharyngeal carcinoma by modulating the expression of
other genes, besides regulating p16Ink4a. Also, in the
present study, we did not observe a significant correla-
tion between Bmi-1 expression and either p16Ink4a or
p14ARF expression in ovarian carcinoma cohorts. This
data provided evidence that Bmi-1 does act through
other molecular targets than repression of p16Ink4a/
p14ARF in ovarian carcinogenesis. Recently, it was
reported that by applying a mouse/human comparative
translational genomics approach, a Bmi-1-driven 11-
gene signature was identified. This cohort of 11 genes
was confirmed to be a magic marker of stem cell-ness
and therapy failure in patients with a variety of aggres-
sive tumors [18]. Clearly, further work needs to be done
to more precisely understand the molecular mechanism
of Bmi-1 in the development and progression of ovarian
carcinoma, as well as other human cancers.
With regard to the mechanism of up-regulated protein
expression of Bmi-1 in ovarian carcinomas, it is known
that gene amplification is a common pathological
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mechanism of gene overexpression in human cancers
[30]. To determine whether the overexpression of Bmi-1
in ovarian carcinomas was caused by gene amplification,
the amplification status of Bmi-1 was examined by
FISH. In our 96 informative cases of ovarian carcinomas
by both IHC and FISH simultaneously, intensive expres-
sion of Bmi-1 was detected in all (8/8) ovarian car-
cinomas that had Bmi-1 amplification. However,
amplification of Bmi-1 was not observed in 28 other
ovarian carcinomas with intensive expression of Bmi-1.
These results indicate that the expression level of Bmi-1
protein in ovarian carcinoma does not always coincide
with gene amplification. In addtion, in bladder cancers,
a significant difference in Bmi-1 protein expression and
in mRNA levels was obtained, but Bmi-1 protein was
up-regulated to a much greater extent than Bmi-1
mRNA in cancer tissue compared with non-cancerous
tissues, implying that the major source of Bmi-1 expres-
sion might be dysregulation at the post-transcriptional
level in bladder cancers [19]. These data suggest that
the up-regulation of protein expression of Bmi-1 in
human cancers is complicated and it might be regulated
not only by gene amplification, but also by other mole-
cular mechanisms including transcriptional regulation
and post-translational regulation.
Conclusion
In summary, in this study, we describe, for the first
time, protein expression and amplification patterns of
Bmi-1 in normal human ovary, benign, borderline and
malignant epithelial ovarian tumor tissues. Our results
provide a basis for the concept that increased expression
of Bmi-1 in human ovarian carcinoma may be important
in the acquisition of an invasive and/or aggressive phe-
notype. In addition, our study introduces Bmi-1 expres-
sion as a new independent prognostic marker in ovarian
carcinoma with intensive expression of Bmi-1 protein in
tumor cells predicting poor outcome of the disease for
the individual patient.
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